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Abstract
The coronavirus disease pandemic has created opportunities for innovation in diabetes
care that were not possible before. From the lens of this “new normal” state, we have an
opportunity to rapidly implement, test, and iterate models of diabetes care to achieve the
quadruple aim of improving medical outcomes, patient experience, provider satisfaction,
and reducing costs. In this perspective, we discuss several innovative diabetes models
of care which promote collaborative care models and improve access to high-quality
specialty diabetes care. We discuss ongoing threats to diabetes care innovation, and
offer practical solutions to foster evolution and sustain current strides made during the
pandemic.
Key Words: healthcare delivery, diabetes care, innovation, alternative models of care, COVID-19; healthcare delivery,
diabetes care, innovation, alternative models of care, COVID-19

A Force of Change
The “new normal” has been coined as a term to denote
the major shift in paradigm that coronavirus disease 2019
(COVID-19) has forced around the globe. In health care,
the “new normal” has fostered innovation and allowed for
real-world testing of care models in unprecedented ways. In
this watershed moment for health care systems around the

world, real change may be possible to create a better new
normal beyond the pandemic if careful steps are taken to
promote advocacy and ensure sustainability.
For diabetes, which affects half a billion people worldwide, the thrust toward innovation has long been overdue.
Achieving optimal glycemic control on a large scale has
major implications for population and economic health,

ISSN Print 0021-972X ISSN Online 1945-7197
Printed in USA
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium,
provided the original work is properly cited.

https://academic.oup.com/jcem   e377

Downloaded from https://academic.oup.com/jcem/article/106/1/e377/5921164 by guest on 31 August 2021

Shivani Agarwal,1 Michelle L. Griffith,2 Elizabeth J. Murphy,3 Carol Greenlee,4
Jeffrey Boord,5 and Robert A. Gabbay6; for the Innovative Models of
Diabetes Care Taskforce of the Endocrine Society

e378 

The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. 106, No. 1

Innovations in Diabetes Care
We review in detail here models that each of the Taskforce
members have had success with. Specifically, these models
focus on improving access to high-quality specialty endocrinology care through care coordination and opening lines
of communication.
Clinically, each of these models is applicable to both
type 1 and type 2 diabetes. Although historically, some of
these innovations have been more popular to a particular
type of diabetes, they are becoming increasingly relevant
across the spectrum because there is wider distribution of
both types of diabetes across the lifespan and technological
treatments traditionally reserved for type 1 diabetes are
now being used for type 2 diabetes as well.

Telemedicine
Telemedicine has become a critical strategy to improve
access to diabetes care while simultaneously supporting
necessary physical distancing during the pandemic, representing one of the biggest and swiftest care transformations worldwide. There is a large body of evidence for
the efficacy of traditional telemedicine in diabetes care
(real-time audiovisual visits), showing parity in outcomes
with traditional office visits (3). The advent of connected
technologies such as insulin pumps, smart insulin pens,
and continuous glucose monitors lend themselves to virtual modalities of sharing patient information. For patient
populations with less technology literacy or lower wi-fi
bandwidth, telephone visits are also possible to increase access to necessary care. Practices can choose from a number
of technology platforms to facilitate telemedicine, including

existing electronic health record (EHR) and other commercially available tools. Options for sharing glucose data
include newer cloud-based platforms versus traditional
self-reporting of blood sugar logs; however, technological
approaches must match patient population capabilities. In
addition to medical visits, newer models of virtual care delivery by the entire multidisciplinary team has gained favor.
Tele-education, nutrition, and psychology are among the
newest telemedicine models that may bridge longstanding
gaps in required multidisciplinary support and collaboration in diabetes care. Continuation of health technology
platform support and collaboration will be needed to promote infrastructure building and sustainability beyond the
pandemic.

eConsultation
eConsults are another innovation that greatly increases the
collaboration of different service lines, providing access
to high-quality endocrinology care, and was particularly
useful during the pandemic. eConsults are patient-specific,
asynchronous virtual communication between a specialist
and referring provider (typically primary care) that occurs
within a shared EHR or other secure electronic platform.
The benefits of eConsults across specialties are well documented and include increased access to specialty care (4),
provider satisfaction (5), and educational benefits for primary care providers (6). More specifically, eConsults for
diabetes care in the Veterans Administration Health System
have resulted in more rapid access to specialty care with
comparable clinical outcomes to in-person care (7). In
COVID-19, both outpatient and inpatient eConsults have
been pivotal in enabling the specialty endocrinologist to
provide timely and efficient consultation. In addition, it
enables endocrinologist-led foundational education to providers who benefit from real-time feedback on cases, which
can bring back joy to endocrinology work.

Project ECHO
Project ECHO (8) is a scalable, global, evidence-based
telementoring program that aims to build internal capacity of primary care providers for diabetes care through
ongoing case-based learning. The format includes a “hub”
(eg, endocrinologist) that engages with a geographically
dispersed group of primary care clinicians (spokes) by
video, who present their cases on a routine basis and progressively build local diabetes expertise. Initial centralization of knowledge acquisition followed by dissemination
to multiple primary care providers enhances the reach of
endocrinology far beyond specialist capacity, holding great
promise for continued reach of new therapeutics to the
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yet less than 50% of people with diabetes meet glycemic
targets (1, 2). Before the pandemic, innovative models of
diabetes care were slowly gaining recognition, aiming to
achieve improvements in medical outcomes, patient experience, health care provider satisfaction, and reduction
in costs. However, typical roadblocks existed to impede
meaningful change. With COVID-19, implementing alternative models of care on swift and iterative cycles became
the norm.
In 2018, the Endocrine Society convened a taskforce
to examine and promote innovative models of care in diabetes. In this perspective, the members of the taskforce
review several models of care, with which they have experience and which have potential to become standards of
care in the new normal. We discuss the current challenges
to widespread adoption of new models of care. Last, we
provide potential solutions to foster innovation and create
pathways for sustainability.
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masses. Diabetes/endocrinology ECHO programs are currently active in 4 countries and are of greatest value when
targeting primary care providers with limited access to specialty care (e.g., community health centers) (9).

Team-based care

and adult systems is the foundation upon which successful
transition can occur. However, communication and coordination are often missing because of EHR incompatibility for information transfer and deep cultural divides
in pediatric and adult care paradigms that can be jarring
for patients to shift between. Warm handoffs and transition navigator programs have demonstrated improved
collaboration and access to adult care (14, 15). One-page
health care transition summary documents are low-cost,
efficient transfers of information that bridge providers
and enable better therapeutic relationships with patients.
Multidisciplinary team-based support including dieticians,
educators, and psychologists can offer much needed care
coordination and leverage virtual resources, which are now
more readily available in COVID times. Additionally, virtual conferencing among patient, pediatric, and adult provider as a means of orientation that was not feasible before.
As rates of youth-onset type 2 diabetes and young adultonset type 1 diabetes increase, transition care models will
need to be designed for sustainability and implementation
in lower resourced settings.

Threats to Innovation and Sustainability
Pharmacist-led care
The physician-pharmacist collaborative model in primary
care has been shown to be efficacious in many chronic
diseases, including diabetes. Clinical pharmacists have a
PharmD degree and generally complete 1 to 2 years of postgraduate residency training. The pharmacist is embedded
in the primary care or endocrinology practice and provides
expertise in medication management for patients with complex diabetes, including initiation and titration of pharmacotherapy. Pharmacists are able to offload busy providers
by managing a dedicated panel of patients and identifying
and addressing barriers to medication adherence, while
providing high-quality specialty diabetes care that may
not be available elsewhere (11). A retrospective study of a
pharmacist-physician collaborative care model in an integrated health system showed significant improvements in
HbA1c, blood pressure, and cholesterol control as well as a
23% reduction in hospitalizations in the collaborative care
patient group compared with usual care (12). Additionally,
pharmacist collaborative models have been shown to improve outcomes for patients with type 1 diabetes (13).

Pediatric to adult care transition
The transition from pediatric to adult care poses unique
challenges to emerging adults with type 1 and type 2 diabetes who may struggle with the transition to independence
in diabetes self-care. Care coordination between pediatric

Although innovative models of diabetes care were available
in pre-COVID times, dissemination was limited because of
a host of issues, some of which may reemerge once the pandemic ends. Barriers include: (1) lack of generalizable payment models; (2) slow technology integration into health
care; (3) real-world implementation challenges; (4) a dearth
of rigorous outcomes and cost data; (5) workforce shortages from burnout; and (6) no infrastructure for sustainability of innovative models.
Although some countries already had payment models
for innovative diabetes care and more have adopted compensation strategies during the pandemic, it remains unclear whether coverage of innovative services will continue.
Efforts to innovate care have typically been limited to
institutions or practitioners with external funding or to
integrated payor-provider systems, leading to a lack of generalizability and sustainability. Of late, health systems and
stakeholders have increased their appetite for care strategies
that work to improve medical outcomes and cut costs, even
if not traditionally implemented. However, sustainability of
pay models will rely on rigorous and large-scale outcome
and cost data, which so far remains scarce.
In addition, lack of a roadmap for sustainability of
innovation continues to threaten real change. Features
of EHR workflows that facilitate telemedicine and
e-Consults require extensive builds or funds to partner
with third-party companies. Hardware and software support in addition to training on new technologies requires
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Within a team-based care model, a variety of team members have specific roles and responsibilities for ensuring
patients receive optimal diabetes care. A shift from “the
doctor takes care of patients and delegates significant work
to team members” to “we take care of patients” (10) promotes collaborative care that can reduce burnout from
clinical care demands while enhancing communication and
access to quality diabetes care. During COVID-19, with
virtual care models, the dissolution of in-person huddles
and team meetings has made it difficult to sustain teambased care approaches; however, these shortcomings have
been balanced with more access to ancillary services than
previously. More innovation to enhance virtual communication among care teams is needed to provide optimal
multidisciplinary diabetes care.
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Recommendations for a Better New Normal
To promote lasting health care transformation and create a
better new normal for the health care community and our
patients with diabetes, we must create systems that promote pathways for success and sustainability. Following
are recommendations for all levels of stakeholders, which
will help to ensure that innovation is sustained beyond the
current pandemic. Professional Societies:
• Create virtual platforms, networks, and in-person
meeting opportunities for health care practitioners to
share practice transformation ideas and pilot project
results

• Enhance training opportunities in quality improvement
methodologies and formulation of the business case for
innovation
• Leverage professional society relationships to advocate
at the governmental level for alternative reimbursement
models that facilitate innovation
• Encourage collaboration of primary care and specialty care
professional societies to foster cross-collaborative networks
such as quality improvement learning collaboratives, joint
national meetings, and shared practice guidelines
• Foster technology-healthcare industry collaboration,
and integration of health care redesign approaches into
clinical practice settings
Healthcare Institutions and Practices:
• Encourage health care practitioners to incorporate quality
improvement and implementation science methods in
routine care
• Allocate philanthropic funding to promote clinical
innovation and obtain pilot outcomes and cost data that
can garner longstanding institutional or payor support
• Provide time for regular practice meetings to discuss
innovative solutions to common clinical challenges
supported through data collection
• Foster mentorship of clinicians to identify clinical
improvements
• Enable multidisciplinary collaboration with service
lines outside of endocrinology to build and sustain
infrastructure for communication and innovation
• Encourage beta testing and early stage collaboration with
health technology companies to introduce nontraditional
frameworks of care
Health Care Practitioners:
• Seek virtual training opportunities in quality improvement
methodology and dissemination-implementation science
• Search for mentorship and collaboration within or
outside practice setting to discover best practices and
learnings from failed experiences
• Understand organizational priorities and align initiatives
by actively approaching administrators
• Recruit multiple team members (eg, nursing, practice
managers, allied health care practitioners) to create a
unified voice in advocating for change

Conclusions
Faced with an unprecedented public health threat with the
arrival of the COVID-19 pandemic, the value of innovative models of diabetes care is clearer than ever before.
The pandemic has presented a disruptive force to health
care worldwide. The response has been an embrace of
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financial and staff resources that most nonacademic institutions are not able to provide. Lack of interoperability
of different EHRs limits communication between care
sites that are not part of the same institution. Continually
siloed health centers and cultural differences in paradigms of care prevent different provider groups (for example, pediatric and adult counterparts or primary and
endocrine care) from working together, even within the
same health system. These systems of care, if not altered
in more permanent ways, will continue to challenge foundational changes.
Moreover, continuing to align with organizational priorities will allow for continual support of strides made in
health care. However, making a business case for these innovations is difficult. Many innovations require up-front
investment and continued support from health care or governmental organizations. Endocrinologists also often lack
the training, vocabulary, and pilot data to effectively advocate for budgets for innovative ideas. Moreover, the success
of business cases somewhat relies on the environment in
which the care is being practiced, whether fee for service or
value-based system. This will continue to be relevant after
the pandemic ends.
Finally, maintaining an impassioned and highly skilled
workforce of endocrinologists to carry innovation forward remains the ultimate challenge. Before the pandemic
and even more so now because of cost-limiting measures,
both endocrinology teams and operations staff can be
overwhelmed with routine work, having little time or resources to pursue innovation, even if the interest is there.
Overall, fewer trainees are entering the field of endocrinology, limiting the influx of new ideas that are necessary
for innovation. Although diabetes care can attract trainees
from multiple disciplines, the increased administrative
aspects of outpatient care greatly diminish the joys of
work, leading to increased rates of burnout and mental
health issues.
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innovation in diabetes care. Longstanding challenges were
overcome seemingly overnight, showing us the great potential of innovative models. These successes in implementation have yet to be fully scaled, although with each passing
month, we get closer to a better new normal. We are on the
brink of a complete redesign in health care. Advocacy and
community will be tantamount to the continued forward
momentum we have gained. We must monopolize on this
unique opportunity to reshape our current history into a
positive and hopeful future.
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